The financials
CRISPR Therapeutics AG by the numbers
Its largest product in 2026-Q1 was Collaboration at $1.0M, 69% of the disclosed total, just ahead of Grant at 31%.
| Product | Revenue | Share |
|---|---|---|
| Collaboration | $1.0M | 69% |
| Grant | $458K | 31% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $1.5M (+64%)
Grant grew -47% year on year
Segment Latestquarter on quarteryear on year
- Collaboration$1.0M$1.0MQoQ -year on year ---
- Grant$458.0K$458.0KQoQ -48%year on year -47%-48%-47%